The J&J/ Vanderbilt Tie-Up: Accessing Innovation On The Cheap
This article was originally published in Start Up
Executive Summary
With most Big Pharmas facing a steep and costly patent chasm and in-house R&D failing to produce the necessary bridge to patent-challenged franchises, companies have been forced to look for new sources of innovation beyond traditional in-licensing and acquisition. As a result, some drugmakers are looking with renewed interest at the innovation housed in universities. The tie-up between Johnson & Johnson and Vanderbilt University is just the latest example of this important trend.
You may also be interested in...
Vanderbilt's Neuroscience Unit Operates Like A Biotech
A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.
Vanderbilt's Neuroscience Unit Operates Like A Biotech
A small drug-discovery shop within Vanderbilt University Medical Center shows how a focused approach can lead to top-notch results in the so-called translational research space. The Vanderbilt Center for Neuroscience Drug Discovery, continues to garner NIH grants as well as milestone-based payments from the biopharma industry via serially inking drug discovery deals centered around one specialized area: addressing brain-linked disorders through the modulation of glutamate receptors.
Vanderbilt Research Into GlyT1 Inhibition May Result In New Approach To Treating Schizophrenia
Vanderbilt's Center for Neuroscience Drug Discovery licenses three preclinical GlyT1 candidates to Karuna Pharmaceuticals, one of three business development actions by the center in recent weeks.